Ohshima Nobuharu, Akeda Yukihiro, Nagai Hideaki, Oishi Kazunori
Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital , Tokyo, Japan.
Department of Infection Control and Prevention, Graduate School of Medicine, Osaka University , Osaka, Japan.
Hum Vaccin Immunother. 2020 Sep 1;16(9):2285-2291. doi: 10.1080/21645515.2020.1718975. Epub 2020 Feb 12.
An observational study to assess immunogenicity before and after the first, second, and third vaccinations with the 23-valent pneumococcal polysaccharide vaccine in a cohort of 16 elderly patients with chronic lung diseases was conducted. The safety of this vaccine was also compared between the first, second, and third vaccinations. Serotype-specific immunoglobulin G (IgG) and the opsonization index (OI) for serotypes 6B, 14, 19F, and 23F were analyzed, and adverse local and systemic reactions were compared. The levels of serotype-specific IgG and OI increased significantly 1 month after the first, second, and third vaccinations. Peak IgG levels were higher after the third vaccination than after the second vaccination, but the levels of serotypes 6B, 14, and 19F were not higher than after the first vaccination. Serotype-specific OIs did not differ after the third vaccination compared with the first and second vaccinations. The level of serotype-specific IgG required for killing 50% of bacteria decreased significantly 1 month after the second vaccination. This level was slightly elevated immediately before the third vaccination but decreased after the third vaccination. Although self-limited local and systemic reactions were more frequent after the second and third vaccinations than after the first vaccination, no serious systemic reactions were seen after any vaccination. These data suggest that sustained functional serotype-specific IgG is produced after the first, second, and third vaccinations and they confirm the safety of the second and third vaccinations in elderly people with chronic lung disease.
对16名患有慢性肺部疾病的老年患者组成的队列进行了一项观察性研究，以评估23价肺炎球菌多糖疫苗首次、第二次和第三次接种前后的免疫原性。还比较了该疫苗在首次、第二次和第三次接种之间的安全性。分析了6B、14、19F和23F血清型的血清型特异性免疫球蛋白G（IgG）和调理指数（OI），并比较了局部和全身不良反应。首次、第二次和第三次接种后1个月，血清型特异性IgG和OI水平显著升高。第三次接种后的IgG峰值水平高于第二次接种后，但6B、14和19F血清型的水平不高于首次接种后。第三次接种后的血清型特异性OI与首次和第二次接种后相比无差异。第二次接种后1个月，杀死50%细菌所需的血清型特异性IgG水平显著降低。该水平在第三次接种前立即略有升高，但在第三次接种后降低。虽然第二次和第三次接种后比第一次接种后更频繁出现自限性局部和全身反应，但任何一次接种后均未出现严重的全身反应。这些数据表明，首次、第二次和第三次接种后产生了持续的功能性血清型特异性IgG，并且证实了第二次和第三次接种对患有慢性肺病的老年人的安全性。
